Daniel C Maneval
Overview
Explore the profile of Daniel C Maneval including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1013
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nolan R, Kang D, Maneval D, Knowles S, LaBarre M, Printz M
J Control Release
. 2024 Aug;
374:369-383.
PMID: 39089505
Hyaluronan (HA) is a glycosaminoglycan that forms a gel-like barrier in the subcutaneous (SC) space, limiting bulk fluid flow and the dispersion of SC-administered therapeutics. Recombinant human hyaluronidase PH20 (rHuPH20)...
2.
Cui T, Corrales-Guerrero S, Castro-Aceituno V, Nair S, Maneval D, Monnig C, et al.
Mol Ther Oncolytics
. 2023 Sep;
30:181-192.
PMID: 37674628
Albumin is an attractive candidate carrier for the development of novel therapeutic drugs. Gemcitabine has been FDA approved for the treatment of solid tumors; however, new drugs that optimize gemcitabine...
3.
Printz M, Sugarman B, Paladini R, Jorge M, Wang Y, Kang D, et al.
AAPS J
. 2022 Oct;
24(6):110.
PMID: 36266598
Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investigated rHuPH20 immunogenicity risk through...
4.
Blair A, Wang J, Davelaar J, Baker A, Li K, Niu N, et al.
Gastroenterology
. 2022 Jun;
163(5):1267-1280.e7.
PMID: 35718227
Background & Aims: The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immunosuppressive nature and therapeutic resistance. Herein we sought to modify signaling and enhance immunotherapy efficacy by targeting...
5.
Heineman T, Baumgart M, Nanavati C, Gabrail N, Van Wart S, Mager D, et al.
Clin Transl Sci
. 2021 May;
14(5):1875-1885.
PMID: 33982408
This open-label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non-small...
6.
Printz M, Dychter S, DeNoia E, Harrigan R, Sugarman B, Zepeda M, et al.
Curr Ther Res Clin Exp
. 2020 Sep;
93:100604.
PMID: 32963641
Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronidase-zzxf], and Darzalex FASPRO [daratumumab and...
7.
Zhao C, Thompson B, Chen K, Gao F, Blouw B, Marella M, et al.
Oncotarget
. 2019 Nov;
10(61):6561-6576.
PMID: 31762938
Hyaluronan accumulation in the tumor microenvironment is associated with poor prognosis in several solid human cancers. To understand the role of stromal hyaluronan in tumor progression, we engineered 3T3HAS3, a...
8.
Locke K, Maneval D, LaBarre M
Drug Deliv
. 2019 Feb;
26(1):98-106.
PMID: 30744432
ENHANZE drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co-administered therapeutics. rHuPH20 works by...
9.
Li X, Shepard H, Cowell J, Zhao C, Osgood R, Rosengren S, et al.
Clin Cancer Res
. 2018 Aug;
24(19):4798-4807.
PMID: 30084839
The tumor microenvironment (TME) evolves to support tumor progression. One marker of more aggressive malignancy is hyaluronan (HA) accumulation. Here, we characterize biological and physical changes associated with HA-accumulating (HA-high)...
10.
Infante J, Korn R, Rosen L, LoRusso P, Dychter S, Zhu J, et al.
Br J Cancer
. 2018 Jan;
118(2):e3.
PMID: 29361630
This corrects the article DOI: 10.1038/bjc.2017.327.